2상모집 중
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
연구 개요
The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided into 2 sub-studies/parts designated Part 1 and Part 2 that will enroll in sequence starting with Part 1 followed by Part 2.
- 스폰서
- 협력: BMS
- 적응증
- Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
- 중재
- Nivolumab, Nivolumab + Relatlimab, Ipilimumab
- 목표 등록
- 90명
- 시작일
- 2024-05-17
- 완료(예정)
- 2028-11-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.